In newly diagnosed AML, ivosidenib or enasidenib in combination with intensive chemotherapy resulted in IDH1 and IDH2-MRDneg of 16/41 (39%) and 15/64 (23%) and MFC-MRDneg in 16/20 (80%) and 10/16 (63%) among patients achieving CR/CRi/CRp, respectively [91]. Here, IDH2 is linked to acute myeloid leukemia.